logo Ibionextlogo Ibionext
  • HOME
  • ABOUT US
  • STRATEGY
  • TEAM
  • OUR COMPANIES
  • NEWS & MEDIA
  • CONTACT
  • Français
Twitter
LinkedIn

iBionext in Biotech Finances

February 19, 2018NewsIbionext

“iBionext a finalisé, à 90 M€, le closing de son premier fonds, iBionext Growth Fund. Ces moyens vont lui permettre d’accompagner les sociétés de son portefeuille dans la « Vallée de la mort », entre l’amorçage et le développement late stage. ”

https://www.eei-biotechfinances.com/sommaire-de-biotech-finances-n-800-accinov-integragen-sublimed-cellprothera-ibionext-alzheimer/

 

Previous post Les confidentiels business de Capital Finance sur Radio Classique Next post iBionext Growth Fund strengthens its participation in Prophesee

SEARCH

ARCHIVES

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

CATEGORIES

  • Events (3)
  • News (78)
  • Press releases (67)

LATEST NEWS

  • Théa partners with Tilak Healthcare to promote OdySight: First remote monitoring solution for ophthalmology June 29, 2022
  • GrAI Matter Labs Unveils Life-Ready AI with GrAI VIP at GLOBAL INDUSTRIE May 16, 2022
  • Rigshospitalet, the main hospital in Denmark based in Copenhagen, collaborate with Chronolife for a clinical investigation in Oncology March 31, 2022
  • Europrotect partners with Chronolife for the development and production of a device to measure physiological data, integrated into a firefighter’s intervention suit to limit the risk of thermal stress March 13, 2022
  • OdySight, first remote monitoring solution in ophthalmology to be reimbursed by the Social Security March 9, 2022

CONTACT US

74, rue du Faubourg Saint-Antoine 75012 Paris
+33 1 76 21 47 50
contact@ibionext.com

LEGAL NOTICES

  • Cookies Policy
  • Privacy Policy
  • Terms of use
© 2023 iBionext. All rights reserved